Analysis of time to next treatment (TTNT) in melflufen and dexamethasone-treated patients (pts) with relapsed/refractory multiple myeloma (RRMM).

被引：0
|
作者：
Bringhen, Sara
Richardson, Paul G.
Voorhees, Peter Michael
Plesner, Torben
Mellqvist, Ulf-Henrik
Zonder, Jeffrey A.
Reeves, Brandi Nikcole
Zavisic, Stojan
Harmenberg, Johan
Obermueller, Jakob
Sonneveld, Pieter
机构：
[1] Univ Torino, Div Hematol, Turin, Italy
[2] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Carolinas Hlth Care Syst, Levine Canc Inst, Charlotte, NC USA
[4] Vejle Hosp, Dept Hematol, Vejle, Denmark
[5] Boras Hosp, Boras, Sweden
[6] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
[7] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA
[8] Oncopeptides AB, Stockholm, Sweden
[9] Erasmus MC, Rotterdam, Netherlands
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8043
引用
收藏
页数：2
相关论文
共 50 条
  • [31] A US BUDGET IMPACT MODEL FOR SELINEXOR IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
    Bassali, J.
    Gould, I
    Mladsi, D. D.
    Kaye, J. A.
    Shah, J.
    Mehta, J.
    VALUE IN HEALTH, 2020, 23 : S33 - S33
  • [32] Durvalumab (DURVA) plus daratumumab (DARA) in patients (pts) with relapsed and refractory multiple myeloma (RRMM).
    Richardson, Paul G.
    Bensinger, William
    Weisel, Katja C.
    Boyd, Kevin
    Ramasamy, Karthik
    Gonzalez, Esther
    Favre-Kontula, Linda
    Peluso, Teresa
    Sternas, Lars Axel
    Di Casoli, Carl
    Zaki, Mohamed H.
    Facon, Thierry
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [33] TREATMENT OF MULTIPLE RELAPSED/REFRACTORY MYELOMA WITH LENALIDOMIDE DEXAMETHASONE RETROSPECTIVE ANALYSIS OF 65 PATIENTS TREATED AT A CENTER
    Moya Arnao, M.
    Cabanas Perianes, V
    Moreno Balmonte, M. J.
    Martinez Marin, A.
    Fernandez Poveda, E.
    Navarro Almenzar, B.
    Berenguer Piqueras, M.
    Salido Fierez, E.
    Labbadia, F.
    Perez Lopez, R.
    Garcia Hernandez, A. M.
    Cerezo Manchado, J. J.
    Blanquer Blanquer, M.
    Martinez Garcia, A. B.
    Melero Amor, A.
    Garcia Candel, F.
    Moraleda Jimenez, J. M.
    HAEMATOLOGICA, 2017, 102 : 97 - +
  • [34] Phase I Trial of Ibrutinib, Lenalidomide and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)
    Ailawadhi, Sikander
    Paulus, Aneel
    Alegria, Victoria R.
    Laplant, Betsy
    Moustafa, Muhamad Alhaj
    Chapin, Dustin
    Jackson, Keisha
    Jani, Prachi
    Ahmed, Salman
    Edwards, Brett
    Manna, Alak
    Roy, Vivek
    Sher, Taimur
    Chanan-Khan, Asher A.
    BLOOD, 2019, 134
  • [35] PANOBINOSTATPK/PD IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITHRELAPSED AND RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM).
    Mu, S.
    Tajima, T.
    Corrado, C.
    Sunami, K.
    Suzuki, K.
    Hino, M.
    Kuroda, Y.
    Shibayama, H.
    Lin, R.
    Waldron, E.
    Binlich, F.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S49 - S49
  • [36] Treatment patterns among patients with relapsed/refractory multiple myeloma (RRMM) in Taiwan
    Huang, Jeffrey Shang-Yi
    Wang, Ming-Chung
    Yeh, Su-Peng
    Chen, Tsai-Yun
    Teng, Chieh-Lin Jerry
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S188 - S189
  • [37] Cost Offsets in the Treatment Journeys of Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Ailawadhi, Sikander
    DerSarkissian, Maral
    Duh, Mei Sheng
    Lafeuille, Marie-Helene
    Posner, George
    Ralston, Stephen
    Zagadailov, Erin
    Ba-Mancini, Abbie
    Rifkin, Robert M.
    BLOOD, 2017, 130
  • [38] Duration of Therapy (DOT) and Time to Next Therapy (TTNT) of Bortezomib, Carfilzomib and Ixazomib Combinations with Lenalidomide/Dexamethasone (VRd, KRd, IRd) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Clinical Practice in the United States Vs Clinical Trial Experience
    Chari, Ajai
    Romanus, Dorothy
    Luptakova, Katarina
    Raju, Aditya
    Farrelly, Eileen
    Blazer, Marlo
    Skacel, Tomas
    Hari, Parameswaran
    BLOOD, 2017, 130
  • [39] CLINICAL AND TREATMENT CHARACTERISTICS OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN EUROPE
    Oriol, A.
    Steinmetz, T.
    Patel, V
    Kutikova, L.
    Schmidt, N.
    Hennies, N.
    Thiess, A.
    Kostev, K.
    Leleu, X.
    VALUE IN HEALTH, 2019, 22 : S497 - S498
  • [40] A single-center treatment sequencing analysis in patients with relapsed/refractory multiple myeloma (RRMM)
    Kumar, Swarup
    Clark, Jackson
    Alvarez-Soto, Alvaro
    El Warrak, Samantha
    Kumar, Shruthi
    Braish, Julie
    Reddy, Aswanth
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S190 - S191
12345